succinylcholine has been researched along with Neuroleptic Malignant Syndrome in 12 studies
Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH) may have a common pathogenic mechanism; therefore, it has been suggested that known triggering agents for MH (such as succinylcholine) should be avoided in patients with NMS." | 7.69 | Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine? ( Brull, SJ; Kelly, D, 1994) |
| "Neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH) may have a common pathogenic mechanism; therefore, it has been suggested that known triggering agents for MH (such as succinylcholine) should be avoided in patients with NMS." | 3.69 | Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine? ( Brull, SJ; Kelly, D, 1994) |
| "There was no evidence of malignant hyperthermia (MH) in patients receiving succinylcholine, suggesting that an association between NMS and MH may not be clinically relevant in patients being treated with ECT." | 1.27 | ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. ( Addonizio, G; Susman, VL, 1987) |
| "A case of neuroleptic malignant syndrome (NMS) treated successfully with electroconvulsive therapy (ETC) is described." | 1.27 | A successful electroconvulsive treatment of neuroleptic malignant syndrome. ( Aizenberg, D; Hermesh, H; Weizman, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koster, TD | 1 |
| Kooistra, WE | 1 |
| Tuinman, AG | 1 |
| Greenwood, M | 1 |
| Meechan, JG | 1 |
| Saeki, N | 1 |
| Kwon, R | 1 |
| Migita, T | 1 |
| Fukuda, H | 1 |
| Hamada, H | 1 |
| Kawamoto, M | 1 |
| Kelly, D | 1 |
| Brull, SJ | 1 |
| Stemp, LI | 1 |
| Takagi, A | 1 |
| Addonizio, G | 2 |
| Susman, VL | 1 |
| Geiduschek, J | 1 |
| Cohen, SA | 1 |
| Khan, A | 1 |
| Cullen, BF | 1 |
| Hermesh, H | 1 |
| Aizenberg, D | 1 |
| Weizman, A | 1 |
| George, AL | 1 |
| Wood, CA | 1 |
| Susman, V | 1 |
1 review available for succinylcholine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
[Toxic and adverse effects of local anesthetics/neuromuscular blocker: lidocaine, succinylcholine].
Topics: Anesthetics, Local; Drug Interactions; Humans; Hypokalemia; Hypotension; Lidocaine; Muscle Rigidity; | 1999 |
11 other studies available for succinylcholine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Near miss with succinylcholine for electroconvulsive therapy: a case report.
Topics: Adult; Electrocardiography; Electroconvulsive Therapy; Female; Humans; Hyperkalemia; Neuroleptic Mal | 2014 |
General medicine and surgery for dental practitioners. Part 2--metabolic disorders.
Topics: Amyloidosis; Anesthetics, Local; Apnea; Carbohydrate Metabolism, Inborn Errors; Dental Care for Chro | 2010 |
Electroconvulsive therapy using rocuronium and sugammadex in patient with neuroleptic malignant syndrome.
Topics: Androstanols; Bipolar Disorder; Diabetes Insipidus; Electroconvulsive Therapy; Female; gamma-Cyclode | 2011 |
Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?
Topics: Adult; Anesthesia, Intravenous; Bipolar Disorder; Creatine Kinase; Electroconvulsive Therapy; Female | 1994 |
Management of lethal catatonia with dantrolene sodium.
Topics: Catatonia; Dantrolene; Electroconvulsive Therapy; Humans; Malignant Hyperthermia; Neuroleptic Malign | 1993 |
ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Bipolar Disorder; Catatonia; Diagnosi | 1987 |
Repeated anesthesia for a patient with neuroleptic malignant syndrome.
Topics: Adult; Anesthesia; Electroconvulsive Therapy; Humans; Male; Malignant Hyperthermia; Neuroleptic Mali | 1988 |
Role of electroconvulsive therapy in neuroleptic malignant syndrome (NMS)
Topics: Electroconvulsive Therapy; Humans; Malignant Hyperthermia; Neuroleptic Malignant Syndrome; Succinylc | 1987 |
A successful electroconvulsive treatment of neuroleptic malignant syndrome.
Topics: Adult; Chlorpromazine; Electroconvulsive Therapy; Humans; Male; Neuroleptic Malignant Syndrome; Schi | 1987 |
Succinylcholine-induced hyperkalemia complicating the neuroleptic malignant syndrome.
Topics: Adult; Humans; Hyperkalemia; Male; Neuroleptic Malignant Syndrome; Rhabdomyolysis; Succinylcholine | 1987 |
Neuroleptic malignant syndrome and use of anesthetic agents.
Topics: Anesthetics; Halothane; Humans; Malignant Hyperthermia; Neuroleptic Malignant Syndrome; Succinylchol | 1986 |